Core Viewpoint - The new materials industry in China is experiencing rapid growth driven by policy support, market demand, and technological innovation, with a projected total output value of 8.48 trillion yuan in 2024, maintaining double-digit growth for 14 consecutive years [1][3][20]. Group 1: Industry Definition and Classification - New materials refer to recently developed or developing structural and functional materials with superior properties. They can be classified into structural materials and functional materials based on their usage, and further categorized into four types: metal materials, inorganic non-metal materials, organic polymer materials, and advanced composite materials [1]. Group 2: Current Development Status - The new materials industry has expanded significantly, with the government focusing on electronic information materials, aerospace materials, new energy materials, and environmentally friendly materials. National high-tech industrial bases for new materials have been established in seven cities [3][5]. Group 3: Market Size and Structure - In 2024, the chemical new materials market is expected to account for approximately 22.08% of the total new materials market in China, while battery new materials will represent about 6.66%. By 2025, these figures are projected to be 21.75% and 6.97%, respectively [7]. Group 4: Competitive Landscape - Major companies in the new materials sector include Lens Technology, Antai Technology, China National Materials, and others, which are enhancing their international competitiveness through technological innovation and market expansion [12][16]. Group 5: Development Trends - The demand for new materials is increasing due to the rapid development of downstream industries such as information technology and new energy. The industry is transitioning towards low-carbon and green development, supported by significant technological advancements [20][23].

Core Viewpoint - The article discusses the ongoing projects and strategic developments of Kaisa Bio, highlighting the delays in their major production projects and the establishment of new production bases in response to market demands and infrastructure changes [1][3][4]. Group 1: Project Developments - Kaisa Bio's project in the Shanxi Synthetic Biology Industrial Park is experiencing delays due to changes in infrastructure planning, affecting the annual production of 900,000 tons of bio-based polyamide [1][3]. - The company has completed a production line capable of producing 5,000 tons of bio-based high-temperature polyamide, which meets current demands for continuous fiber composite materials [1][2]. - The total investment for the Shanxi project is planned at 80 billion yuan, with the first phase involving 45 billion yuan and the second phase 35 billion yuan, aiming for a total output value exceeding 100 billion yuan upon completion [2]. Group 2: Strategic Partnerships - In May 2024, Kaisa Bio signed a strategic cooperation agreement with the Hefei municipal government and China Merchants Group to establish a joint venture focused on bio-based polyamide composite materials [4]. - The Hefei project aims to create an industrial ecosystem for bio-based materials, with the establishment of a company for research, production, and sales of bio-based polyamide composites [4]. - The collaboration is expected to enhance the development of a complete industrial chain for bio-based materials, positioning Kaisa Bio as a key player in the bio-based materials market [4].

Core Viewpoint - The article discusses the establishment and investment plans of招商凯赛生物材料 (Zhongshan Kaisa Biochemical Materials) in the production of bio-based composite materials, highlighting its commitment to green and sustainable manufacturing practices. Group 1: Project Overview - 招商凯赛生物材料 plans to invest 468.5 million yuan in an annual production project of 41,000 tons of bio-based composite materials, which includes 20,000 tons/year of composite products, 3,000 tons/year of photovoltaic frame products, and 18,000 tons/year of construction template products. The project is scheduled to be built from April 2025 to December 2026 [1]. - The bio-based polyamide is produced from renewable biomass resources, utilizing biological, chemical, and physical methods to create monomers for synthetic polyamide, resulting in a polymer material that is green, environmentally friendly, and renewable [1]. Group 2: Company Background - 招商凯赛生物材料 was established in December 2024, funded by Shanghai Kaisa Biotechnology Co., Ltd. The company focuses on the research and production of bio-based polyamide resins for composite product processing, emphasizing the green, low-carbon, and energy-saving characteristics of its products [2]. - The company has been actively developing new materials such as bio-based long-chain polyamides and high-temperature polyamides, while also promoting innovative projects like continuous fiber-reinforced bio-based polyamide composites and the utilization of agricultural waste [2]. Group 3: Collaboration and Future Plans - In May 2024, Hefei City signed a tripartite cooperation agreement with 招商创科 and 凯赛生物 to advance the development of the bio-manufacturing industry, with a total investment of approximately 5 billion yuan planned for the project in two phases [2]. - The first phase involves an investment of 1 billion yuan, which includes the composite project and bio-based polyamide modification project, while the second phase plans to invest 4 billion yuan, focusing on further capacity expansion and collaborations with companies like 宁德时代 and 韩国3P公司 [2].

Core Insights - Synthetic biology is at a pivotal growth point in China, attracting significant attention from global investors due to its unique innovation potential and broad application prospects [1] - The Chinese synthetic biology market comprises 116 listed companies, including technology platform providers, CXO companies offering biosynthesis solutions, and chemical and pharmaceutical companies seeking transformation [1] - The industry showcases a mix of established players with decades of experience and newly founded companies, highlighting the vast development potential and imagination space behind synthetic biology [1] Industry Overview - Enabling technology companies in synthetic biology are experiencing rapid growth, leveraging cutting-edge technologies such as gene editing, gene synthesis, gene sequencing, big data, and machine learning [1] - Current enabling technologies are still in their early stages, with high technical barriers, leading companies to pursue collaborations with universities, research institutions, and other enterprises to advance R&D [1] Leading Companies - BGI Genomics and Berry Genomics are recognized as leaders among enabling technology companies in China's synthetic biology sector [2] - BGI Genomics focuses on gene sequencing instruments, laboratory automation, and new business areas, enhancing its global influence in precision medicine and health [3] - Berry Genomics, a leader in gene sequencing, offers services in reproductive health, genetic disease detection, and tumor detection, supported by proprietary technologies like PCR-free methods [6] Platform Companies - Synthetic biology platform companies primarily provide services related to process improvement and enzyme engineering, with few achieving the functionality of cell factories [9] - Kingfisher Biotech is a prominent global gene supplier, evolving into a leading provider of research and production services with a strong reputation in life sciences [11] - Yikole Biotech specializes in synthetic biology technology, focusing on biomanufacturing and possessing a vast library of over 20,000 enzymes [13][16] Emerging Trends - The Chinese synthetic biology sector is witnessing a surge in investment opportunities driven by policy guidance and market demand, with companies increasing their focus on technological innovation and R&D [22] - Key application areas include biopharmaceutical raw materials, bio-based materials, and the development of cell and gene therapy drugs, supported by integrated R&D and production capabilities [16][20]

（一） 股东大会召开的时间：2025 年 5 月 16 日 证券代码：688065 证券简称：凯赛生物 公告编号：2025-027 上海凯赛生物技术股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 | 股东类型 | 同意 | | 反对 | | 弃权 | | | --- | --- | --- | --- | --- | --- | --- | | | 票数 | 比例（%） | 票数 | 比例（%） | 票数 | 比例（%） | | 普通股 | 480,100,167 | 99.9685 | 148,524 | 0.0309 | 2,700 | 0.0006 | （二） 股东大会召开的地点：上海市闵行区绿洲环路 396 弄 11 号 9 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 156 | | --- ...

上海市锦天城律师事务所 关于上海凯赛生物技术股份有限公司 2025 年第一次临时股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海凯赛生物技术股份有限公司 2025 年第一次临时股东大会的 1 法律意见书 致：上海凯赛生物技术股份有限公司 根据《中华人民共和国证券法（2019 年修订）》（以下简称"《证券法》"） 《中华人民共和国公司法（2023 修订）》（以下简称"《公司法》"）和中国 证券监督管理委员会《上市公司股东会规则》等法律、法规和其他有关规范性文 件的要求，上海市锦天城律师事务所（以下简称"本所"）接受上海凯赛生物技 术股份有限公司（以下简称"凯赛生物"或"公司"）的委托，指派律师参加公 司 2025 年第一次临时股东大会（以下简称"本次股东大会"或"本次会议"）。 上海市锦天城律师事务所 法律意见书 为出具本《法律意见书》，本所声明如下： 1、本所律师仅对本次股东大会的召集程序、召开程序、出席会议人 ...

Core Viewpoint - The article highlights the increasing presence and application of bio-based materials at the CHINAPLAS 2025 International Rubber and Plastics Exhibition, indicating a shift towards high-end and significant use cases beyond single-use products and packaging, signaling a burgeoning industry ready for growth [1]. Group 1: Company Innovations - Jinhai Technology is exploring a "recycling + bio-based" composite technology path, using bio-based BDO to replace part of petroleum-based raw materials, resulting in a chemical recycling PBT resin with a bio-based content of 31% [4]. - Kasei Biotech focuses on bio-based materials for low-carbon applications in automotive lightweighting, electronics, industrial products, rail transportation, and consumer goods, showcasing innovations in battery boxes, structural components, and thermal management systems [9]. - Arkema presents a series of bio-based, recyclable, lightweight, and high-durability specialty material solutions aimed at low-carbon living and advanced manufacturing [15]. Group 2: Material Applications - Kasei's bio-based polyamide materials are innovatively applied in various sectors, including electric vehicle battery boxes and interior/exterior components [9]. - Rilsan® PA11 from Arkema, derived from castor beans, is 100% bio-based and fully recyclable, with a carbon footprint reduced to 1.3 kg CO2e/kg, approximately 80% less than conventional petroleum-based polyamides [22]. - SK Chemicals has developed bio-based PU foam shoe uppers made from ECOTRION, showcasing the versatility of bio-based materials in footwear [26]. Group 3: Exhibition Highlights - The exhibition features a wide array of bio-based innovations, including CovationBio's bioPTMEG, a bio-based alternative to petroleum-based PTMEG, demonstrating excellent durability and elasticity for high-performance applications [34]. - Leaf Bio showcases its core exhibits, including 100% bio-based polyester PEF bottle chips and BioFleax™ fibers, emphasizing environmental and comfort characteristics for diverse applications [37]. - eSUN highlights its environmentally friendly materials based on PLA, including fibers, yarns, and biodegradable packaging applications, showcasing the potential of bio-based materials in various sectors [38]. Group 4: Future Events - The 10th Bio-based Conference and Exhibition will take place from May 25 to May 27, 2025, in Shanghai, featuring discussions on bio-based industry strategies, innovations in key chemicals and materials, and sustainable applications across various sectors [70][72].

上海凯赛生物技术股份有限公司 上海凯赛生物技术股份有限公司 关于股东大会开设网络投票提示服务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海凯赛生物技术股份有限公司（以下简称"公司"）拟于 2025 年 5 月 16 日 14:00 召开 2025 年第一次临时股东大会，本次会议采用现场投票和网络投票 相结合的表决方式，详见公司于 2025 年 4 月 15 日在上海证券交易所网站 （www.sse.com.cn）披露的公司《关于召开 2025 年第一次临时股东大会的通知》 （公告编号：2025-018）。 为更好地服务广大中小投资者，确保有投票意愿的中小投资者能够及时参会、 及时投票，公司拟使用上证所信息网络有限公司（以下简称"上证信息"）提供 的股东大会提醒服务，委托上证信息通过智能短信等形式，根据股权登记日的股 东名册主动提醒股东参会投票，向每一位投资者主动推送股东大会参会邀请、议 案情况等信息。投资者在收到智能短信后，可根据《上市公司股东会网络投票一 键通服务用户使用手册》（下载链接：https://vot ...

证券代码：688065 证券简称：凯赛生物 公告编号：2025-024 上海凯赛生物技术股份有限公司 关于召开 2024 年度暨 2025 第一季度 业绩说明会的公告 一、说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2024 年度及 2025 年第一季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在 信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 5 月 15 日（星期四）10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2025 年 5 月 9 日（星期五）至 5 月 14 日（星期三）16:00 前登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " ...

证券代码：688065 证券简称：凯赛生物 公告编号：2025-025 上海凯赛生物技术股份有限公司 关于召开 2025 年上海辖区上市公司年报 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 5 月 15 日 （星期四） 15:00-16:30 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2025 年 5 月 15 日（星期四）15:00-16:30 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 三、参加人员 董事长、总裁：刘修才博士 投资者可 ...